UNSPSC 51151644: Homatropine

This classification denotes an antimuscarinic agent with the molecular formula C17H24NO3.Br, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 68JRS2HC1C, chemically known as 8-azoniabicyclo(3.2.1)octane, 3-((hydroxyphenylacetyl)oxy)-8,8-dimethyl-, bromide, endo- but generally known as homatropine methylbromide, which bears US NIH Compound Identifier 6646. European Medicines Agency schedules Homatropine methylbromide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08048MIG.

UNSPSC 51151644 Homatropine is a Commodity code for a specific pharmaceutical agent, but state and local procurement activity under this code does not reflect purchases of homatropine itself. The most recent state and local opportunities tagged to this code show a mismatch between the code's nominal scope and the work actually being solicited. Seminole County, Florida issued IFB 60459723LAS seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually through competitive bidding, with quarterly deliveries to the Seminole County Community Health Building in Sanford and a response deadline of July 26, 2023. The Texas Health and Human Services Commission posted RFI HHS0017013 on April 3, 2026 to gather vendor capabilities regarding direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager arrangements, seeking experience with self-insured employer and government health plan contracting and value-based pricing models. Neither solicitation addresses homatropine procurement specifically.

The limited recent activity under this code spans two states — Florida and Texas — with issuing bodies ranging from county health departments to state health agencies. The Seminole County opportunity targets emergency response and harm-reduction initiatives with fixed-fee contracting, drug-free workplace certification, E-Verify compliance, and potential FEMA funding, while the Texas RFI functions as exploratory market intelligence rather than a formal competitive solicitation. The code shows little relevant recent activity aligned with its nominal pharmaceutical scope, suggesting either infrequent homatropine procurement through state and local channels or systematic misclassification of pharmaceutical solicitations in the taxonomy.